Navigation Links
Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Date:10/3/2007

A Fully Automated, Portable Solution for In-Clinic and Out-Reach Influenza

Testing

PORTON DOWN, England, October 3 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics and detection systems, announces a EUR3 million award from the European Commission Framework 7 programme to the RANGER consortium. The award will fund the development and validation of a fully automated, low cost system for the rapid diagnosis of influenza infections and subtypes.

The RANGER consortium, which is coordinated by Enigma Diagnostics, comprises leading technology companies including Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV and PERA who will contribute to the development of the instrument and assays. The consortium also includes the Health Protection Agency, the UK's national reference laboratory for influenza diagnostics, and the Queen Sirikit National Institute of Child Health who will evaluate and validate the system.

The system will be based on Enigma's proprietary and fully-automated instrumentation technology, which integrates sample preparation with real-time polymerase chain reaction (PCR) to detect viral RNA in a full range of clinical samples. The simple-to-use, portable system will provide rapid results direct to medical staff in a near-patient or out-reach environment in both the developed and developing world.

By providing laboratory standard, high specificity and sensitivity PCR results in a decentralised setting, the system will advance the diagnosis of early stage viral infections and the surveillance of disease outbreaks.

Enigma is also separately developing real-time PCR-based diagnostics systems targeting chlamydia, gonorrhoea and other sexually transmitted infections.

John McKinley, Chairman of Enigma Diagnostics, said: "The award of this grant and the strength of our consortium partners is a great endorsement of Enigma's technology. It is also a strategically important milestone for the company as it demonstrates the utility of our real time PCR in what is an extremely challenging area of diagnosis. We are confident we will be able to deliver a system that rapidly and simply delivers laboratory quality results at the point of care."


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Diagnostics Corporation
2. Roche Diagnostics Corporation
3. A prognosis for GE and Abbott Diagnostics
4. The world of in-vitro diagnostics is another Midwest success story
5. The world of in vitro diagnostics is another Midwest success story
6. Midwest holds strong position in worldwide diagnostics business
7. BioDiagnostics is first seed-testing lab to gain new accreditation
8. Speaker announces business members of IT Task Force
9. Doyle announces technology tax credits for Berbee
10. Doyle announces new energy, global warming policies
11. Doyle announces $80M renewable energy strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/24/2017)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing ... Leader event to highlight new clinical data that will ... the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company,s ... in-person and via live webcast on Tuesday, February 28 ... the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):